Testing effectiveness (Phase 2)Active Not RecruitingNCT06087263
What this trial is testing
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
Who this might be right for
Gastrointestinal Stromal Tumors
M.D. Anderson Cancer Center 3